A Novel Strategy for Development of an Effective HIV/AIDS Vaccine
Posted Apr 28 2011 8:00pm
Description of Invention: The invention offered for licensing and commercial development relates to the field of HIV/AIDS Vaccines. More specifically, the invention describes a novel strategy that can be useful in effective vaccination and treatment of HIV/AIDS infected persons. In this strategy (called ‘trigger-and-neutralize’ strategy) the infected subject is primed with HIV trimeric gp 120 immunogen to induce the production of CD4i (CD4-induced) antibodies. The patient is then treated with a compound that stabilizes the ‘open’ conformation of the gp120 of the HIV virus, at which conformation the gp120 epitope is better exposed and effectively neutralized by the CD4i antibodies.
Applications: Vaccination and treatment of HIV/AIDS infected patients.
Advantages: The unique strategy of eliciting CD4i antibodies in vivo and ensuring their neutralizing effect by stabilizing the gp120 open conformation, will provide more effective treatment compared to other published methods that utilize neutralizing antibodies to treat HIV/AIDS.
Development Status: The subject matter of the invention continues to be researched. Proof-of-principle of some of the aspects of the invention have been demonstrated.
Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008 Sep 4;455(7209):109-113. [ PubMed: 18668044 ]
White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, M. de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain dependent variation in quaternary structure. PLoS Pathog. 2010 Dec 23;6(12):e1001249. [ PubMed: 21203482 ]
Felts RL, Narayan K, Estes JD, Shi D, Trubey CM, Fu J, Hartnell LM, Ruthel GT, Schneider DK, Nagashima K, Bess JW Jr, Bavari S, Lowekamp BC, Bliss D, Lifson JD, Subramaniam S. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13336-13341. [ PubMed: 20624966 ]
Licensing Status: Available for licensing and commercial development.
Collaborative Research Opportunity: The Center for Cancer Research, NCI/NIH is seeking statements of capability or interest from parties interested in collaborative research to further develop, produce, evaluate, or commercialize trimeric gp120 immunogens. Please contact John Hewes, Ph.D. at 301-435-3121 or email@example.com for more information.
For Licensing Information Please Contact: John Stansberry Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5236 Fax: 301-402-0220